GlassScriptPhysician profile
Andrew D Lancaster
NPI 1992842934
$5,819.48
in general payments reported to CMS, 2019-2025
26 companies · $1,749 in 2025
The $1,749 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,385 · 2020: $264 · 2021: $230 · 2022: $312 · 2023: $928 · 2024: $951 · 2025: $1,749.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,512 · Travel and Lodging: $1,116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,511.83 |
| Travel and Lodging | $1,115.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,662.15 | 2021-2025 | Minimed 780g |
| Tandem Diabetes Care, INC. | $869.84 | 2019-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Amgen INC. | $442.19 | 2019-2024 | Prolia, Evenity, Repatha |
| Insulet Corporation | $399.11 | 2022-2025 | Omnipod, Omnipod |
| Sanofi-Aventis U.S. LLC | $313.69 | 2019-2024 | |
| Xeris Pharmaceuticals, INC. | $282.72 | 2021-2024 | Recorlev |
| Lilly USA, LLC | $271.91 | 2019-2024 | Mounjaro, Jardiance |
| Beta Bionics, INC. | $202.72 | 2024 | Ilet Bionic Pancreas |
| Novo Nordisk INC | $193.86 | 2019-2024 | Ozempic, Rybelsus |
| Horizon Therapeutics Plc | $180.98 | 2022-2023 | Tepezza |
| Neurocrine Biosciences, INC. | $139.29 | 2025 | |
| Radius Health, INC. | $116.62 | 2024 | Tymlos |
| Bayer Healthcare Pharmaceuticals INC. | $116.35 | 2021-2023 | |
| Abbott Laboratories | $113.31 | 2020-2023 | Freestyle Libre 3 |
| Inspire Medical Systems, INC. | $109.25 | 2023 | Inspire |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Minimed, INC. | $82.01 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $62.34 | 2019-2020 | |
| Dexcom, INC. | $58.32 | 2024 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $42.51 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $38.59 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.64 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $23.42 | 2022 | |
| Amryt Pharma Holdings LTD | $18.33 | 2023 | Mycapssa |
| Fresenius USA Marketing, INC. | $17.57 | 2021 | |
| Ge Healthcare | $16.76 | 2024 | |
| Alexion Pharmaceuticals, INC. | $14.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Lancaster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.